EP0058780A1 - Procédé de détermination d'antigènes ou d'anticorps - Google Patents
Procédé de détermination d'antigènes ou d'anticorps Download PDFInfo
- Publication number
- EP0058780A1 EP0058780A1 EP81110764A EP81110764A EP0058780A1 EP 0058780 A1 EP0058780 A1 EP 0058780A1 EP 81110764 A EP81110764 A EP 81110764A EP 81110764 A EP81110764 A EP 81110764A EP 0058780 A1 EP0058780 A1 EP 0058780A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- antigens
- immunoglobulin
- container
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 46
- 102000036639 antigens Human genes 0.000 title claims abstract description 46
- 108091007433 antigens Proteins 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 31
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 23
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 239000013049 sediment Substances 0.000 claims abstract description 8
- 238000005119 centrifugation Methods 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims abstract description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000002022 anti-cellular effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- ZFEKVFJKFDZSHE-UHFFFAOYSA-M sodium;2-aminoacetic acid;chloride Chemical compound [Na+].[Cl-].NCC(O)=O ZFEKVFJKFDZSHE-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/828—Protein A
Definitions
- an immunoglobulin-binding component is bound directly to the plastic material of the cuvette and can thus be used in the adherence test to find X-Anti-A which are bound to the cells. In this way, washing steps are eliminated and the sensitivity of the test is increased.
- the present invention accordingly relates to a method for determining antigens or antibodies in a liquid by incubating particles which have antigens on the surface and antibodies, either the antigens or the antibodies being of known specificity, which is characterized in that introduces the antigen / antibody complex into a container with a conical or wedge-shaped bottom recess, at least the recess of the container being coated with an immunoglobulin-binding component which is directed against the antibodies, and after centrifugation the amount of sediment is determined, whereby the antigen / antibody complex is freed of unbound immunoglobulins before and / or after introduction into the container.
- Anti-immunoglobulins or protein A isolated from Staphylococcus aureus can be considered as immunoglobulin-binding components, although it should be noted that protein A only binds the immunoglobulins G, as is known.
- the method according to the present invention is particularly suitable for determining viral, cellular or erythrocyte antigens or antiviral, anticellular or antierythrocytic antibodies.
- Antigens from hepatitis B, influenza, Rabies, Rubella and the like come into consideration as viral antigens to be determined.
- Cellular antigens to be determined are, in particular, HLA series antigens and tumor antigens.
- HLA series antigens and tumor antigens.
- erythrocytic antigens blood group antigens, rhesus antigens, Kell antigens, MNS antigens, Lewis antigens and Duffy antigens come into consideration.
- Antibodies to be determined are those which are formed in the body as a response to the above-mentioned antigens.
- the liquid in which the antigens or antibodies are detected can be a biological liquid, such as blood, serum, plasma, urine, cerebrospinal fluid, lymphatic fluid or saliva.
- the liquid in which the antigens or antibodies are detected can also be a buffered saline solution, e.g. B. be phosphate buffered saline.
- a liquid with a low ionic strength can also be considered, for example an aqueous solution containing 0.24 M / 1 glycine, 0.003 M / 1 Na 2 HPO 4 .12 H 2 0, 0.003 M / 1 NaH 2 P0 4. 2 H 2 O, 0.03 M / 1 NaCl and O, 1 g / 1 NaN 3 .
- a cuvette or the well of a microtiter plate can be considered as a container with a conical or wedge-shaped bottom well, in which the determination of antigens or antibodies is carried out.
- anti-immunoglobulins are used as the immunoglobulin-binding component, they do not necessarily have to be used in a purified form, but it is advantageous to use them in a purified form. Affinity chromatography is particularly suitable as a purification method.
- the conical or wedge-shaped recesses in the bottom of the container need not be coated with the immunoglobulin-binding component immediately before the test; rather, it is possible to coat these conical or wedge-shaped depressions of the containers with the immunoglobulin-binding component, wash them out with water and dry them in air, whereupon the containers coated in this way can be stored in the refrigerator at 4 ° C.
- protein A which binds to immunoglobulin G, or anti-immunoglobulins can be used as immunoglobulin-binding components.
- Anti-immunoglobulins which can be used are those which are directed against the immunoglobulin subclasses of the antibodies. However, it is also possible to use, as anti-immunoglobulins, those which are directed against the light chains of the antibodies and thus offer a broader use since they are directed against all classes of immunoglobulins.
- the conical or wedge-shaped recesses in the bottom of the containers are coated with the anti-immunoglobulins in a conventional manner.
- the antigen / antibody complex is freed of unbound immunoglobulins before or after being introduced into the container. If this step is carried out before being introduced into the container, it is carried out in a conventional manner, ie by adding a buffer such as phosphate-buffered saline, centrifuging and decanting, this process being repeated several times. if this step is only carried out after it has been introduced into the container, it is carried out by centrifuging the liquid containing the antigen / antibody complex through a cushion consisting of a further liquid, the density of the liquid of the cushion being greater than the density the other liquid.
- the pillow liquid must not be toxic and must have a suitable pH (eg in the range of 6-8). Furthermore, this pillow liquid must not change the layer sequence.
- pillow liquids examples include bovine serum albumin, fetal calf serum and polyvinylpyrrolidone.
- the amount of sediment is determined after centrifugation, this preferably being done by measuring the sediment area proportional to it.
- Erythrocytes are particularly suitable as particles that have antigens on the surface.
- the antigen / antibody determination method according to the invention can be done both manually and by apparatus, e.g. with the device described in German Offenlegungsschrift No. 29 07 823.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1104/81 | 1981-02-19 | ||
| CH110481 | 1981-02-19 | ||
| CH7613/81 | 1981-11-27 | ||
| CH761381 | 1981-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0058780A1 true EP0058780A1 (fr) | 1982-09-01 |
| EP0058780B1 EP0058780B1 (fr) | 1987-03-04 |
Family
ID=25686662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP81110764A Expired EP0058780B1 (fr) | 1981-02-19 | 1981-12-24 | Procédé de détermination d'antigènes ou d'anticorps |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4560647A (fr) |
| EP (1) | EP0058780B1 (fr) |
| CA (1) | CA1179260A (fr) |
| DE (1) | DE3175955D1 (fr) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2577321A1 (fr) * | 1985-02-08 | 1986-08-14 | Lapierre Yves | Dispositif et procede de mise en evidence d'agglutinats erythrocytaires |
| EP0078734B1 (fr) * | 1981-10-29 | 1986-10-15 | BIOMERIEUX, Société Anonyme dite | Procédé de dosage immunologique mettant en oeuvre deux anticorps, le deuxième anticorps étant purifié par chromatographie d'affinité, supports pour sa mise en oeuvre |
| EP0313318A1 (fr) * | 1987-10-20 | 1989-04-26 | The Wellcome Foundation Limited | Essai immunologique |
| EP0363510A1 (fr) * | 1988-10-12 | 1990-04-18 | Biotest AG | Procédés de recherche et d'identification des anticorps d'érythrocyte à l'aide d'une méthode à phase solide |
| EP0398292A3 (fr) * | 1989-05-19 | 1991-11-13 | Eisai Co., Ltd. | Composition diagnostique pour l'arthrite rheumatoide |
| EP0487459A1 (fr) * | 1990-11-22 | 1992-05-27 | Dimitrios Dr. Giannitsis | Procédé pour la détection d'anticorps |
| US5213963A (en) * | 1988-10-12 | 1993-05-25 | Biotest Aktiengesellschaft | Procedure for finding and identifying red cell antibodies by means of the solid phase method |
| WO2012010666A1 (fr) | 2010-07-21 | 2012-01-26 | Diagast | Méthodes d'immunodiagnostic magnétique et nécessaires révélant la présence de complexes anticorps/antigènes dans le cadre du groupage et du phénotypage du sang érythrocytaire |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122446A (en) * | 1987-04-17 | 1992-06-16 | New York University | Method for detecting antibodies to human immunodeficiency virus |
| US5780248A (en) | 1993-07-15 | 1998-07-14 | Ortho Diagnostic Systems, Inc. | Foil sealed cassette for agglutination reactions and liner therefor |
| US5731157A (en) * | 1993-12-30 | 1998-03-24 | The Procter And Gamble Company | Two-site allergen immunoassay |
| US5589336A (en) * | 1994-11-10 | 1996-12-31 | New York Blood Center | Diagnostic method and kit for determining Kell blood group genotype |
| NL1003570C2 (nl) * | 1996-07-11 | 1998-01-15 | Stichting Centraal Lab | Methode voor antigeen- en antistofbepaling in de bloedgroepserologie. |
| US6933109B2 (en) * | 2000-12-22 | 2005-08-23 | Large Scale Proteomics Corporation | Rapid particle detection |
| FR2892820B1 (fr) * | 2005-11-03 | 2008-02-01 | Diagast Soc Par Actions Simpli | Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin |
| WO2008124021A1 (fr) * | 2007-04-03 | 2008-10-16 | Clavina Diagnostics, Inc. | Procédé de détection des réactions antigènes/anticorps des globules rouges |
| EP2986307A4 (fr) * | 2014-01-03 | 2017-04-12 | Bio-rad Laboratories, Inc. | Élimination des impuretés des éluats de la protéine a |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| CN108680756A (zh) * | 2018-05-21 | 2018-10-19 | 中国科学院苏州生物医学工程技术研究所 | 一种不完全抗体检测试剂盒及检测方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2273281A1 (fr) * | 1974-05-29 | 1975-12-26 | Pharmacia Diagnostics Ab | |
| US4048298A (en) * | 1975-02-25 | 1977-09-13 | Rohm And Haas Company | Solid phase double-antibody radioimmunoassay procedure |
| FR2359422A1 (fr) * | 1976-07-23 | 1978-02-17 | Dynatech Holdings Ltd | Plaque pour micro-tests |
| FR2418463A1 (fr) * | 1978-02-28 | 1979-09-21 | Nal Transfusion Sanguine Centr | Procede pour le depistage ou l'identification, dans un milieu biologique, d'antigenes viraux, d'antigenes erythrocytaires ou cellulaires ou d'anticorps |
| DE2907823A1 (de) * | 1978-03-01 | 1979-10-11 | Centre Nat Transfusion | Vorrichtung zum zentrifugieren von fluessigkeiten |
| FR2433749A1 (fr) * | 1978-07-28 | 1980-03-14 | Abbott Lab | Procede de determination immunologique d'anticorps specifiques d'une classe d'antigenes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
| US4169138A (en) * | 1974-05-29 | 1979-09-25 | Pharmacia Diagnostics Ab | Method for the detection of antibodies |
| CH588700A5 (fr) * | 1975-02-28 | 1977-06-15 | Hoffmann La Roche | |
| US4021534A (en) * | 1975-12-12 | 1977-05-03 | Hoffmann-La Roche Inc. | Radioimmunoassay |
-
1981
- 1981-12-24 DE DE8181110764T patent/DE3175955D1/de not_active Expired
- 1981-12-24 EP EP81110764A patent/EP0058780B1/fr not_active Expired
-
1982
- 1982-01-12 CA CA000393925A patent/CA1179260A/fr not_active Expired
-
1984
- 1984-01-30 US US06/575,237 patent/US4560647A/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2273281A1 (fr) * | 1974-05-29 | 1975-12-26 | Pharmacia Diagnostics Ab | |
| US4048298A (en) * | 1975-02-25 | 1977-09-13 | Rohm And Haas Company | Solid phase double-antibody radioimmunoassay procedure |
| FR2359422A1 (fr) * | 1976-07-23 | 1978-02-17 | Dynatech Holdings Ltd | Plaque pour micro-tests |
| FR2418463A1 (fr) * | 1978-02-28 | 1979-09-21 | Nal Transfusion Sanguine Centr | Procede pour le depistage ou l'identification, dans un milieu biologique, d'antigenes viraux, d'antigenes erythrocytaires ou cellulaires ou d'anticorps |
| DE2907823A1 (de) * | 1978-03-01 | 1979-10-11 | Centre Nat Transfusion | Vorrichtung zum zentrifugieren von fluessigkeiten |
| FR2433749A1 (fr) * | 1978-07-28 | 1980-03-14 | Abbott Lab | Procede de determination immunologique d'anticorps specifiques d'une classe d'antigenes |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0078734B1 (fr) * | 1981-10-29 | 1986-10-15 | BIOMERIEUX, Société Anonyme dite | Procédé de dosage immunologique mettant en oeuvre deux anticorps, le deuxième anticorps étant purifié par chromatographie d'affinité, supports pour sa mise en oeuvre |
| FR2577321A1 (fr) * | 1985-02-08 | 1986-08-14 | Lapierre Yves | Dispositif et procede de mise en evidence d'agglutinats erythrocytaires |
| EP0313318A1 (fr) * | 1987-10-20 | 1989-04-26 | The Wellcome Foundation Limited | Essai immunologique |
| EP0363510A1 (fr) * | 1988-10-12 | 1990-04-18 | Biotest AG | Procédés de recherche et d'identification des anticorps d'érythrocyte à l'aide d'une méthode à phase solide |
| US5213963A (en) * | 1988-10-12 | 1993-05-25 | Biotest Aktiengesellschaft | Procedure for finding and identifying red cell antibodies by means of the solid phase method |
| EP0398292A3 (fr) * | 1989-05-19 | 1991-11-13 | Eisai Co., Ltd. | Composition diagnostique pour l'arthrite rheumatoide |
| EP0487459A1 (fr) * | 1990-11-22 | 1992-05-27 | Dimitrios Dr. Giannitsis | Procédé pour la détection d'anticorps |
| WO2012010666A1 (fr) | 2010-07-21 | 2012-01-26 | Diagast | Méthodes d'immunodiagnostic magnétique et nécessaires révélant la présence de complexes anticorps/antigènes dans le cadre du groupage et du phénotypage du sang érythrocytaire |
| US9618518B2 (en) | 2010-07-21 | 2017-04-11 | Diagast | Magnetic immunodiagnostic methods and kit for the demonstration of antibody/antigen complexes in erythrocyte blood grouping and phenotyping |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0058780B1 (fr) | 1987-03-04 |
| US4560647A (en) | 1985-12-24 |
| DE3175955D1 (en) | 1987-04-09 |
| CA1179260A (fr) | 1984-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0058780B1 (fr) | Procédé de détermination d'antigènes ou d'anticorps | |
| DE2902676C2 (de) | Verfahren zur Analyse eines von RF oder C1q verschiedenen Antigens im Serum mittels eines Immunoassays | |
| EP0008432B1 (fr) | Procédé de détermination immunologique | |
| DE68919565T2 (de) | Immuntestverfahren unter Verwendung magnetischer Markerteilchen. | |
| DE3882705T3 (de) | Immunoglobulin-bestimmungsverfahren. | |
| CH650592A5 (de) | Reagenz zur verwendung bei immunoassays sowie verfahren zur durchfuehrung des immunoassays. | |
| EP0292810B1 (fr) | Essai immunologique à un seul cycle de traitement pour déterminer des anticorps antigènes spécifiques dans une des classes d'immunoglobulines A,M,D ou E et réactif pour cela | |
| EP0544869B2 (fr) | Procede immunologique de depistage d'anticorps dans des liquides biologiques et kit de mise en oeuvre du procede | |
| DE3873877T2 (de) | Bestimmung von monokinen. | |
| EP0291086B1 (fr) | Procédé pour déterminer un anticorps dans des liquides du corps humain | |
| CH649306A5 (de) | Traegergebundenes immunglobulin-spaltprodukt und seine verwendung fuer immunologische analysenverfahren. | |
| DE68918643T2 (de) | Artikel zur Durchführung von Immuntests unter Verwendung von organischen Farbstoffen sowie Methoden zu seiner Herstellung und seiner Verwendung. | |
| DE3685818T2 (de) | Immunkomplextestverfahren. | |
| EP0363510B1 (fr) | Procédés de recherche et d'identification des anticorps d'érythrocyte à l'aide d'une méthode à phase solide | |
| AT395076B (de) | Vorrichtung und verfahren fuer die diagnostische bestimmung klinischer parameter | |
| EP0379216B1 (fr) | Méthode et réactif pour déterminer une substance détectable immunologiquement | |
| EP0366092B1 (fr) | Procédé pour déterminer des anticorps antigène- et classes-spécifiques et réactif pour ce procédé | |
| EP0015473A1 (fr) | Procédé pour immobiliser des cellules | |
| DE19505266C1 (de) | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren | |
| DE3887727T2 (de) | Partikelstabilisierte Epitope zur Standardisierung und Kontrolle von Immuntests. | |
| DE2816830A1 (de) | Antikoerper-doppelbeschichtetes testroehrchen und seine verwendung im radioimmunassay | |
| EP0322813A2 (fr) | Méthode pour la détermination d'une substance ayant une activité immunologique | |
| EP0554657B1 (fr) | Méthode pour la détermination d'antigènes ou d'anticorps dans la présence d'une complexe immunologique | |
| EP0372217B1 (fr) | Essai immunologique en une étape pour déterminer des anticorps antigène-spécifiques de toutes classes d'immunoglobulines et réactif pour cela | |
| DE69317931T2 (de) | Sensibilisierte Erythrozyten, ein Verfahren zu deren Herstellung, und deren Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19811224 |
|
| AK | Designated contracting states |
Designated state(s): CH DE FR GB IT NL |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE FR GB IT LI NL |
|
| ITF | It: translation for a ep patent filed | ||
| REF | Corresponds to: |
Ref document number: 3175955 Country of ref document: DE Date of ref document: 19870409 |
|
| ET | Fr: translation filed | ||
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19871231 Year of fee payment: 7 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881224 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19881231 Ref country code: CH Effective date: 19881231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19890701 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
| GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19890831 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19890901 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |